ImageneBio, Inc.

ImageneBio, Inc. (IKNA) priced its initial public offering on Mar 26, 2021 at $16.00 per share, within its $15.00–$17.00 range, raising $125M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $481.9M. Jefferies was lead-left underwriter, joined by TD Cowen, Credit Suisse and William Blair. Goodwin Procter advised the company and WilmerHale advised the underwriters.

At its 2021 IPO, Ikena Oncology (now ImageneBio) was a targeted oncology company, founded in 2016, developing cancer therapies aimed at key signaling pathways that drive cancer formation and spread, where approved or effective therapies are lacking.

Status

IPO

Ticker

IKNA

Exchange

Nasdaq Global Market

Priced

Mar 26, 2021

IPO price

$16.00

Price range

$15.00–$17.00

Raised

$125M

Market cap at IPO price

$481.9M

First filed

Mar 5, 2021

Underwriters

Jefferies, TD Cowen, Credit Suisse and William Blair

Company counsel

Goodwin Procter

Underwriters' counsel

WilmerHale

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.